{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:40:00Z","timestamp":1792795200929,"version":"4.5.0"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T00:00:00Z","timestamp":1755475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>Chronic myeloid leukemia (CML) patients are at high risk for developing cardiovascular (CV) diseases due to adverse effects of BCR-ABL tyrosine kinase inhibitors.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>The purpose of this study was to compare patient characteristics and in-hospital mortality between CML patients and non-CML patients, who were hospitalized for ischemic heart disease (IHD).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>This study was based on the Japanese Registry of All Cardiac and Vascular Diseases and the Diagnosis Procedure Combination (JROAD-DPC) database. All patients who were first hospitalized for IHD and received percutaneous coronary intervention from April 2012 to March 2021 were extracted. Propensity score matching was used to reduce confounding effects related to differences in patient background. A total of 766 385 patients, in which 371 CML patients were included, were analyzed. CML patients were more likely to be male and less likely to have obesity, hypertension, and dyslipidemia. The number of modifiable CV risk factors (obesity, smoking, hypertension, dyslipidemia, and diabetes mellitus) in CML patients was smaller than in non-CML patients. There was no difference in in-hospital mortality, whether considering all cases or only acute myocardial infarction cases. This was also statistically non-significant after propensity score matching.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>CML patients were hospitalized for IHD with fewer CV risk factors than non-CML patients, and in-hospital mortality was comparable between CML and non-CML patients. These findings emphasize the need for more stringent management of modifiable CV risk factors for CML patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ehjopen\/oeaf101","type":"journal-article","created":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T11:53:49Z","timestamp":1755258829000},"source":"Crossref","is-referenced-by-count":2,"title":["Clinical characteristics and in-hospital mortality of chronic myeloid leukemia patients with ischemic heart disease: insights from the JROAD-DPC registry"],"prefix":"10.1093","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8978-7804","authenticated-orcid":false,"given":"Akito","family":"Shindo","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo , 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3574-9607","authenticated-orcid":false,"given":"Hiroshi","family":"Akazawa","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo , 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomi","family":"Ueda","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo , 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0462-0966","authenticated-orcid":false,"given":"Hiroshi","family":"Kadowaki","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo , 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Ishida","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo , 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0714-7182","authenticated-orcid":false,"given":"Issei","family":"Komuro","sequence":"additional","affiliation":[{"name":"Department of Frontier Cardiovascular Science, Graduate School of Medicine, The University of Tokyo , 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655 ,","place":["Japan"]},{"name":"International University of Health and Welfare , 4-1-26 Akasaka, Minato-ku, Tokyo 107-8402 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,8,18]]},"reference":[{"key":"2025090406130207200_oeaf101-B1","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1016\/S0140-6736(21)01204-6","article-title":"Chronic myeloid leukaemia","volume":"398","author":"Cortes","year":"2021","journal-title":"Lancet"},{"key":"2025090406130207200_oeaf101-B2","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population","volume":"34","author":"Bower","year":"2016","journal-title":"J Clin Oncol"},{"key":"2025090406130207200_oeaf101-B3","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/nrclinonc.2016.139","article-title":"Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?","volume":"14","author":"Rosti","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"2025090406130207200_oeaf101-B4","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1200\/JCO.2015.62.4718","article-title":"Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia","volume":"33","author":"Moslehi","year":"2015","journal-title":"J Clin Oncol"},{"key":"2025090406130207200_oeaf101-B5","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1007\/s12185-021-03126-6","article-title":"Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"113","author":"Lee","year":"2021","journal-title":"Int J Hematol"},{"key":"2025090406130207200_oeaf101-B6","doi-asserted-by":"crossref","first-page":"e579","DOI":"10.1161\/CIR.0000000000000641","article-title":"Cardio-oncology: vascular and metabolic perspectives: a scientific statement from the American Heart Association","volume":"139","author":"Campia","year":"2019","journal-title":"Circulation"},{"key":"2025090406130207200_oeaf101-B7","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41569-020-0347-2","article-title":"Vascular toxic effects of cancer therapies","volume":"17","author":"Herrmann","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"2025090406130207200_oeaf101-B8","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/bloodadvances.2018025874","article-title":"Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs","volume":"3","author":"Jain","year":"2019","journal-title":"Blood Adv"},{"key":"2025090406130207200_oeaf101-B9","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.jacc.2015.07.025","article-title":"Vascular and metabolic implications of novel targeted cancer therapies: focus on kinase inhibitors","volume":"66","author":"Li","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2025090406130207200_oeaf101-B10","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1161\/CIRCULATIONAHA.115.018347","article-title":"Vascular toxicities of cancer therapies: the old and the new\u2013an evolving avenue","volume":"133","author":"Herrmann","year":"2016","journal-title":"Circulation"},{"key":"2025090406130207200_oeaf101-B11","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"2025090406130207200_oeaf101-B12","doi-asserted-by":"crossref","first-page":"43","DOI":"10.6004\/jnccn.2024.0007","article-title":"Chronic myeloid leukemia, version 2.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Shah","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"2025090406130207200_oeaf101-B13","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1253\/circj.CJ-24-0704","article-title":"Hospitalized patients, treatments, and quality of care for cardiovascular diseases in Japan-outline of the nationwide JROAD investigation","volume":"89","author":"Nishi","year":"2024","journal-title":"Circ J"},{"key":"2025090406130207200_oeaf101-B14","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1253\/circj.CJ-16-0196","article-title":"The current status of cardiovascular medicine in Japan-analysis of a large number of health records from a nationwide claim-based database, JROAD-DPC","volume":"80","author":"Yasuda","year":"2016","journal-title":"Circ J"},{"key":"2025090406130207200_oeaf101-B15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jjcc.2009.05.005","article-title":"Modern state of acute myocardial infarction in the interventional era: observational case-control study\u2013Japanese acute coronary syndrome study (JACSS)","volume":"54","author":"Ogawa","year":"2009","journal-title":"J Cardiol"},{"key":"2025090406130207200_oeaf101-B16","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1253\/circj.CJ-09-0619","article-title":"Trends in acute myocardial infarction incidence and mortality over 30 years in Japan: report from the MIYAGI-AMI registry study","volume":"74","author":"Takii","year":"2010","journal-title":"Circ J"},{"key":"2025090406130207200_oeaf101-B17","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N Engl J Med"},{"key":"2025090406130207200_oeaf101-B18","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.clml.2016.01.006","article-title":"Mortality and vascular events among elderly patients with chronic myeloid leukemia: a retrospective analysis of linked SEER-medicare data","volume":"16","author":"Lang","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2025090406130207200_oeaf101-B19","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1182\/blood-2004-07-2514","article-title":"Identification of human chronic myelogenous leukemia progenitor cells with hemangioblastic characteristics","volume":"105","author":"Fang","year":"2005","journal-title":"Blood"},{"key":"2025090406130207200_oeaf101-B20","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.3324\/haematol.2013.086355","article-title":"Mechanism of impaired glucose metabolism during nilotinib therapy in patients with chronic myelogenous leukemia","volume":"98","author":"Racil","year":"2013","journal-title":"Haematologica"},{"key":"2025090406130207200_oeaf101-B21","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.3324\/haematol.2014.104075","article-title":"Early onset hypercholesterolemia induced by the 2nd-generation tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukemia","volume":"99","author":"Rea","year":"2014","journal-title":"Haematologica"},{"key":"2025090406130207200_oeaf101-B22","doi-asserted-by":"crossref","first-page":"33944","DOI":"10.18632\/oncotarget.5580","article-title":"Effects of first- and second-generation tyrosine kinase inhibitor therapy on glucose and lipid metabolism in chronic myeloid leukemia patients: a real clinical problem?","volume":"6","author":"Iurlo","year":"2015","journal-title":"Oncotarget"},{"key":"2025090406130207200_oeaf101-B23","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia"},{"key":"2025090406130207200_oeaf101-B24","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s11936-017-0524-8","article-title":"Cardiovascular complications of targeted therapies for chronic myeloid leukemia","volume":"19","author":"Damrongwatanasuk","year":"2017","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"2025090406130207200_oeaf101-B25","doi-asserted-by":"crossref","first-page":"675811","DOI":"10.3389\/fphys.2021.675811","article-title":"Cardiovascular issues in tyrosine kinase inhibitors treatments for chronic myeloid leukemia: a review","volume":"12","author":"Santoro","year":"2021","journal-title":"Front Physiol"},{"key":"2025090406130207200_oeaf101-B26","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","article-title":"Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial","volume":"132","author":"Cortes","year":"2018","journal-title":"Blood"},{"key":"2025090406130207200_oeaf101-B27","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1038\/leu.2017.245","article-title":"Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site","volume":"31","author":"Hadzijusufovic","year":"2017","journal-title":"Leukemia"},{"key":"2025090406130207200_oeaf101-B28","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/10428194.2018.1466294","article-title":"Bosutinib, dasatinib, imatinib, nilotinib, and ponatinib differentially affect the vascular molecular pathways and functionality of human endothelial cells","volume":"60","author":"Gover-Proaktor","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"2025090406130207200_oeaf101-B29","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.3389\/fphar.2020.01007","article-title":"The risk of arterial thrombosis in patients with chronic myeloid leukemia treated with second and third generation BCR-ABL tyrosine kinase inhibitors may be explained by their impact on endothelial cells: an in-vitro study","volume":"11","author":"Haguet","year":"2020","journal-title":"Front Pharmacol"},{"key":"2025090406130207200_oeaf101-B30","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.thromres.2016.07.019","article-title":"The tyrosine kinase inhibitor, nilotinib potentiates a prothrombotic state","volume":"145","author":"Alhawiti","year":"2016","journal-title":"Thromb Res"},{"key":"2025090406130207200_oeaf101-B31","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s12185-019-02613-1","article-title":"Efficacy and safety of tyrosine kinase inhibitors for newly diagnosed chronic-phase chronic myeloid leukemia over a 5-year period: results from the Japanese registry obtained by the new TARGET system","volume":"109","author":"Kizaki","year":"2019","journal-title":"Int J Hematol"},{"key":"2025090406130207200_oeaf101-B32","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ijcard.2019.10.036","article-title":"Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors","volume":"301","author":"Caocci","year":"2020","journal-title":"Int J Cardiol"},{"key":"2025090406130207200_oeaf101-B33","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/ejh.13081","article-title":"Severe adverse events by tyrosine kinase inhibitors decrease survival rates in patients with newly diagnosed chronic-phase chronic myeloid leukemia","volume":"101","author":"Ota","year":"2018","journal-title":"Eur J Haematol"},{"key":"2025090406130207200_oeaf101-B34","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1253\/circrep.CR-21-0004","article-title":"Validation of acute myocardial infarction and heart failure diagnoses in hospitalized patients with the nationwide claim-based JROAD-DPC database","volume":"3","author":"Nakai","year":"2021","journal-title":"Circ Rep"},{"key":"2025090406130207200_oeaf101-B35","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1161\/01.CIR.97.18.1837","article-title":"Prediction of coronary heart disease using risk factor categories","volume":"97","author":"Wilson","year":"1998","journal-title":"Circulation"},{"key":"2025090406130207200_oeaf101-B36","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1093\/eurheartj\/ehab309","article-title":"SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe","volume":"42","author":"SCORE2 working group and ESC Cardiovascular risk collaboration","year":"2021","journal-title":"Eur Heart J"},{"key":"2025090406130207200_oeaf101-B37","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1161\/CIRCULATIONAHA.123.067626","article-title":"Development and validation of the American Heart Association's PREVENT equations","volume":"149","author":"Khan","year":"2024","journal-title":"Circulation"}],"container-title":["European Heart Journal Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjopen\/advance-article-pdf\/doi\/10.1093\/ehjopen\/oeaf101\/64079425\/oeaf101.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjopen\/article-pdf\/5\/5\/oeaf101\/64079425\/oeaf101.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjopen\/article-pdf\/5\/5\/oeaf101\/64079425\/oeaf101.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T10:13:12Z","timestamp":1756980792000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjopen\/article\/doi\/10.1093\/ehjopen\/oeaf101\/8237528"}},"subtitle":[],"editor":[{"given":"Joerg","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,8,18]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,8,29]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjopen\/oeaf101","relation":{},"ISSN":["2752-4191"],"issn-type":[{"value":"2752-4191","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,8,18]]},"article-number":"oeaf101"}}